Skip to content

Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women

Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03767803
Enrollment
344
Registered
2018-12-07
Start date
2018-10-01
Completion date
2020-12-31
Last updated
2020-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache, Hypertension, Impaired Liver Function, Pre-Eclampsia, Proteinuria in Pregnancy, Pulmonary Edema, Renal Insufficiency, Thrombocytopenia, Visual Impairment

Keywords

Hypertension, Proteinuria, Thrombocytopenia, Renal Insufficiency, Impaired Liver Function, Pulmonary Edema, Cerebral Symptoms, Visual Symptoms

Brief summary

Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.

Detailed description

This multicenter non-interventional observational sample acquisition study is designed to acquire whole-blood samples from pregnant women who present with signs and symptoms of Pre-E and are in the care at an OB-GYN and/or Maternal Fetal Medicine (MFM) site, defined as outpatient centers, clinic sites, and medical offices. Study population includes subjects who are pregnant, of any race or ethnicity, 18 to 45 years of age, 28 0/7 to 36 6/7 weeks' gestational age with a singleton fetus and have provided written informed consent to provide whole blood specimens at one or more study visits.

Interventions

OTHERNon-interventional study

This is an observational, non-interventional study.

Sponsors

Progenity, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Subject is 18 to 45 years of age * Subject is willing to provide informed consent * Subject enrolling at a study OB-GYN or MFM site is in the opinion of the physician able to provide 20 mL of whole blood and will comply with all study procedures * Subject has a singleton fetus of 28 0/7 to 36 6/7 weeks' gestational age using 2014 ACOG Dating Criteria (pregnancies starting as twins but complicated with either vanishing twin syndrome or fetal demise of one twin before 14 weeks, are eligible for inclusion) * Patient presenting with clinical suspicion of Pre-E based on one or more of the following clinical signs and symptoms of Pre-E: * New onset increased blood pressure in otherwise normotensive patient * Worsening hypertension in a patient with pre-existing hypertension * New onset proteinuria or worsening of pre-existing proteinuria * Any other clinical finding typically associated with suspicion of Pre-E and requiring workup to rule-out Pre-E

Exclusion criteria

* Pregnancy is non-viable, as evidenced by absence of fetal cardiac activity * Major fetal anomaly or chromosomal aneuploidy * Current dialysis for kidney failure, including continuous ambulatory peritoneal dialysis

Design outcomes

Primary

MeasureTime frameDescription
Diagnosis of preeclampsia is determined by standard of care.3 monthsObservational, non-interventional sample procurement study in which participants are treated per standard of care

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026